Kinase News and Research

RSS

Two related enzymes play a key role in development of T-ALL

Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.

17 Apr 2012

Scientists transform skin cells directly into induced neurons

Until recently, the production of pluripotent "multipurpose" stem cells from skin cells was considered to be the ultimate new development. In the meantime, it has become possible to directly convert cells of the body into one another - without the time-consuming detour via a pluripotent intermediate stage. However, this method has so far been rather inefficient.

12 Apr 2012

NIMH honors SUNY Downstate professor with MERIT award

Todd C. Sacktor, M.D., distinguished professor of physiology and pharmacology and of neurology at SUNY Downstate Medical Center, has received a MERIT (Method to Extend Research in Time) award from the National Institute of Mental Health (NIMH) for his research on memory.

7 Apr 2012

Crizotinib reduces testosterone levels in men with ALK positive lung cancer

Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.

5 Apr 2012

Positive preclinical results from Cancer Therapeutics' CTX-0294945 plus Avastin study

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced positive preclinical results for CTX-0294945 as an adjuvant therapy to the cancer drug Avastin (bevacizumab - Genentech/Roche). The data is presented today in a late breaking poster at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, USA.

4 Apr 2012

BioScale presents data on phospho-protein analysis of MAP kinase pathway activation state at 103rd AACR

BioScale, Inc. a life science company that develops ultrasensitive protein analysis technology, presented findings of recently completed research studies on phospho-protein analysis of the activation state of the MAP kinase pathway at the 103rd Annual Meeting of the American Association for Cancer Research (AACR), held at McCormick Place in Chicago, Illinois, March 31 - April 4, 2012.

3 Apr 2012

Lilly announces results of three preclinical studies that focus on c-MET receptor

Eli Lilly and Company today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell.

3 Apr 2012

New data demonstrates anti-cancer activities of Oncoprex

New data demonstrating the anti-cancer activities of Oncoprex were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, IL. The study, "Synergistic antitumor activity of AKT inhibitor MK2206 and FUS1 nanoparticles in LKB1 mutant NSCLC" (Meng J, Lara-Guerra H, Ji L, Roth JA) is authored by a team of investigators from The University of Texas MD Anderson Cancer Center.

3 Apr 2012

New preclinical data on ARIAD's ponatinib and AP26113 study presented at AACR meeting

ARIAD Pharmaceuticals, Inc. today announced the presentation of new preclinical data on its investigational pan-BCR-ABL inhibitor, ponatinib, and its investigational dual EGFR-ALK inhibitor, AP26113, at the American Association for Cancer Research Annual Meeting in Chicago.

3 Apr 2012

MAPK/ERK2 pathway plays a major role in mediating testosterone's effects

Testosterone, the primary male sex hormone, appears to have antidepressant properties, but the exact mechanisms underlying its effects have remained unclear. Nicole Carrier and Mohamed Kabbaj, scientists at Florida State University, are actively working to elucidate these mechanisms.

2 Apr 2012

Aurora-A protein plays an important role in head and neck cancer

Researchers at Fox Chase Cancer Center in Philadelphia have found that a protein associated with other cancers appears to also be important in head and neck cancer, and may consequently serve as a good target for new treatments. The findings will be reported at the AACR Annual Meeting 2012 on Sunday, April 1.

2 Apr 2012

Aberrations in translation regulators linked with hormone receptor-positive breast cancer survival

Four proteins involved in translation, the final step of general protein production, are associated with poor prognosis in hormone-receptor-positive breast cancer when they are dysregulated, researchers reported at the AACR Annual Meeting 2012.

2 Apr 2012

Latest updates in clinical practice decision-making in cancer care presented at NCCN 17th conference

The National Comprehensive Cancer Network (NCCN) held the NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care, March 14 - 18 at The Westin Diplomat in Hollywood, Florida. The latest updates in clinical practice decision-making in cancer care were presented, including, but not limited to, the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening and updates to the NCCN Guidelines for Melanoma and Non-Hodgkin's Lymphomas.

29 Mar 2012

Oncothyreon proposes underwritten public offering of common stock

Oncothyreon Inc. today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering.

29 Mar 2012

Clovis commences CO-1686 Phase I/II study in NSCLC

Clovis Oncology, Inc. announced today that the first clinical study of CO-1686 has commenced with the dosing of the first patient at a U.S. study site. CO-1686 is a novel, oral, targeted covalent inhibitor of epidermal growth factor receptor (EGFR) mutations currently being studied for the treatment of non-small cell lung cancer.

29 Mar 2012

Later-stage cancers thrive by finding detours around drug roadblocks

Later-stage cancers thrive by finding detours around roadblocks that cancer drugs put in their path, but a Purdue University biochemist is creating maps that will help drugmakers close more routes and develop better drugs.

28 Mar 2012

Pfizer to present data on ADCs at AACR 2012

Pfizer Oncology will present data from a variety of preclinical and clinical studies of Pfizer's early-stage compounds, including data from Pfizer's investigational antibody-drug conjugate (ADC) portfolio and research evaluating several molecules targeting novel pathways that play a crucial role in basic cellular functions, at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, IL, from March 31-April 4.

27 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012

New cholesterol lowering drugs on the horizon

The new drugs in development by pharmaceutical makers are injectable medications that block a protein called PCSK9. These drugs have shown promise in early clinical trials for slashing bad LDL cholesterol further than widely used statins can alone. Their biggest advocates say PCSK9 blockers have the potential to be the next multibillion-dollar class of heart drugs.

25 Mar 2012

Verapamil drug may reverse diabetes-related death of pancreatic beta cells

A common high-blood-pressure medication appears to reverse the diabetes-related death of pancreatic beta cells, according to a University of Alabama at Birmingham study published today in the journal Diabetes.

23 Mar 2012